AI Article Synopsis
- The study aimed to assess the effectiveness and safety of combining I seed implantation with transcatheter arterial chemoembolization (TACE) for HCC patients with portal vein tumor thrombosis (PVTT).
- The research involved 134 patients diagnosed with primary HCC and PVTT between January 2013 and June 2015.
- Results showed that the combined treatment significantly improved median survival time and survival rates at 6, 12, and 18 months compared to TACE alone, with type III PVTT and larger tumor size being linked to poorer outcomes.
Article Abstract
Aim: The purpose of this study was to evaluate the efficacy and safety of the endovascular implantation of I seed under ultrasound and x-ray guidance combined with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).
Patients & Methods: The study included 134 pathologically proven or clinically confirmed primary HCC patients with PVTT in our hospital from January 2013 to June 2015.
Results & Conclusion: Compared with the TACE treatment alone, the combination therapy of I seed implantation with TACE significantly prolonged the median survival time and improved the 6-, 12- and 18-month survival rates for HCC patients with PVTT. In addition, the type III PVTT and tumor size were independent predictors for poor prognosis of HCC patients with PVTT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2017-0354 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!